Overview
Sponsor-declared trial summary
Phase
Human pharmacology (Phase I) - First administration to humans
Status
Ongoing, recruiting
Participants planned
108
Countries
1
Sites
1
Diabetic Peripheral Neuropathy (DPN)
Key facts
- Sponsor
- Tenvie Therapeutics Inc.
- Participant type
- Patients, Healthy volunteers
- Age range
- 18-64 years
- Gender
- Male and Female
- Therapeutic area
- Phenomena and Processes [G] - Musculoskeletal and Neural Physiological Phenomena [G11], Diseases [C] - Nervous System Diseases [C10]
- Trial duration
- 2 Mar 2026 → ongoing
- Decision date (initial)
- 2026-02-24
- Transition trial
- No
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- No
Trial design
CTIS Part I — objectives, methods, condition coding
Conditions and MedDRA coding
Diabetic Peripheral Neuropathy (DPN)
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Tenvie Therapeutics Inc.
- Sponsor organisation
- Tenvie Therapeutics Inc.
- Address
- 161 Oyster Point Boulevard
- City
- South San Francisco
- Postcode
- 94080-2042
- Country
- United States
Scientific contact point
- Organisation
- Tenvie Therapeutics Inc.
- Contact name
- Chief Medical Officer
Public contact point
- Organisation
- Tenvie Therapeutics Inc.
- Contact name
- Chief Medical Officer
Locations
1 EU/EEA country · 1 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Netherlands | Ongoing, recruiting | 108 | 1 |
| Rest of world | — | 0 | — |
Investigational sites
Centre for Human Drug Research
Neurology, Zernikedreef 8, 2333 CL, Leiden
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Netherlands | 2026-03-02 | 2026-03-06 |
Application history
1 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2026-01-12 | Netherlands | Acceptable 2026-02-24
|
2026-02-24 |